A four-amino-acid peptide called CAQK (Cysteine-Alanine-Glutamine-Lysine) has emerged as a promising therapeutic candidate for traumatic brain injury. This artificially produced peptide was first discovered in 2016 by researchers at Sanford Burnham Prebys Medical Discovery Institute (CA) – it’s like a delivery drone that scientists built to recognize those specific warning signs and go directly to them

Since that time, the National Institutes of Health has continued to support CAQK research through multiple grants, such as a 2025 $2.5 million SBIR award to AivoCode, the biotech company developing CAQK for clinical trials. A resulting 2025 study published in EMBO Molecular Medicine revealed that CAQK possesses intrinsic neuroprotective properties – reducing lesion size, decreasing cell death, and alleviating neuroinflammation in mice with brain injuries. This discovery transforms CAQK from merely a drug delivery vehicle into a potential standalone treatment – a significant advancement in neuroscience research.